Drug Profile
Phentolamine - Ocuphire Pharma
Alternative Names: 0.75% phentolamine ophthalmic solution - Ocularis Pharma; 1% phentolamine mesylate - Ocularis Pharma; Nyxol; Phentolamine mesylate ophthalmic solution - Ocularis Pharma; RYZUMVILatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Ocularis Pharma
- Developer Ocuphire Pharma
- Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Mydriasis
- Phase III Nyctalopia; Presbyopia
- Phase II Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 11 Apr 2024 Ocuphire Pharma initiates enrollment in the phase III LYNX-2 trial in Nyctalopia (Dim light vision disturbances) (Ophthalmic, Solution) in the US (NCT06349759)
- 01 Apr 2024 Ocuphire Pharma initiates the phase III LYNX-2 trial in Nyctalopia (Dim light vision disturbances) (Ophthalmic, Solution) in the US (NCT06349759)
- 01 Apr 2024 Launched for Mydriasis (In adolescents, In children, In the elderly, In adults) in USA (Ophthalmic)